University Hospital, Toulouse

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

192

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

4 drugs in development

Approved1

Phase 21

Preclinical3

By Therapeutic Area

top 4

Neurology

233%

Oncology

233%

Respiratory

117%

Immunology

117%

R&D Momentum

72/100

Pipeline Velocity

42/100

Trial Completion Rate

86/100

Pipeline Concentration

28/100

Pipeline Freshness

67/100

Strategic Signals

↗Early-stage heavy pipeline may seek late-stage partners
↗Active in Respiratory but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 1, 2026

Withdrawn

Is Tele-rehabilitation an Efficacious Alternative to Traditional Center Based Cardiac Rehabilitation After Acute Coronary Syndrome?

Jul 1, 2026

Recruiting

Pilot Study Evaluating the Usability and Functional Impact of Prolonged Home Use of a Wearable Grasping Neuroprosthesis in Subjects With Vascular Hemiparesis - GRASP-HOME

Earlier

Jun 30, 2026TrialDevelopment of a Rule for Predicting the Risk of Intracranial Hemorrhagic Injury in Elderly Patients Contacting SAMU Centre-15 for Head Trauma Following a Fall From Their Height

Jun 30, 2026TrialStudy of PLATelet Functions and Risk Factors for Hemorrhagic Complications in Patients on Extracorporeal Membrane Oxygenation Veno-venous: Prospective Monocentric Cohort

Jun 30, 2026TrialUse of Brain Structural and Functional Connectomes for the Prediction of Neurological Recovery in Coma Patients After Cardiac Arrest

Jun 30, 2026TrialCognitive Dysfunctions Associated With Delirium in Critically-ill ARDS Patients: Diagnostic and Prognostic Electrophysiological Signatures

Jun 30, 2026TrialImpact of VARIation of OXYdo-reduction Potential in Cardiac Surgery on Post-operative Outcome

Jun 30, 2026TrialA Biological Sample Collection Established to Support Pathophysiological Research on Emerging and Potentially Emerging Infectious Diseases, as Well as Their Therapeutic Management.

3 more events

Jun 30, 2026TrialImpact of Genotyping P450 2C19 on Hospitalization Period When Voriconazole Treatment is Started

Jun 24, 2026TrialAllogeneic Intraveinous Injection of Adipose Tissue Derived-mesenchymal Stem Cells in Mild to Moderate Alzheimer Disease: a Phase I/II Trial

Mar 1, 2026TrialAvacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney Involvement

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

AdMSCPhase 2

Systemic Scleroderma

AdMSCPhase 2

Neurology

Alzheimer Disease

CellREADY® drug product IV dose of 100 millionsPreclinical

Progressive Multifocal Leukoencephalopathy

collection of stoolsPreclinical

Oncology

Acute Myeloid Leukemia

intensive chemotherapyPreclinical

Urothelial Carcinoma

collection of stoolsPreclinical

Respiratory

Asthma

Stopping dupilumabApproved

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)